-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Downgrades Tvardi Therapeutics to Underweight, Lowers Price Target to $3

Benzinga·04/20/2026 13:15:51
Listen to the news
Barclays analyst Etzer Darout downgrades Tvardi Therapeutics (NASDAQ:TVRD) from Equal-Weight to Underweight and lowers the price target from $4 to $3.